Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Sickle cell disease explained: symptoms, inheritance and gene therapy

    Sickle cell disease is a group of inherited blood disorders in which an abnormal hemoglobin bends red blood cells into a sickle shape. The sickled cells restrict blood flow, causing severe pain and organ damage. About 100,000 people in the US have it.[1][2][3] Hydroxyurea and other medicines, antibiotics and transfusions manage it, and a bone marrow transplant can cure some people.[4][5][6] In December 2023 the FDA approved the first two gene therapies, Casgevy and Lyfgenia, and since 2025 a federal model has negotiated outcomes-based agreements for them on behalf of state Medicaid programs.[7][8]

    Editor reviewedStrict sourcingUpdated Explainer23 claims · 100% primaryHealth and medicine, Gene editing and gene therapy
    Reading level: 1 passage differs; the rest is the same for everyone.

    This page explains sickle cell disease and its treatments. It is not medical advice. Anyone with sickle cell disease who has a fever, chest pain, trouble breathing or stroke symptoms should get emergency care. Talk to a hematologist about which treatments fit. This page gives no dosing information.

    Sickle cell disease is a group of inherited disorders in which red blood cells contain an abnormal hemoglobin, hemoglobin S, that can bend them into a sickle or crescent shape.[1] The sickled cells restrict blood flow and limit oxygen delivery, leading to severe pain and organ damage.[2]

    Who it affects

    Sickle cell disease affects millions of people worldwide and is most common in people whose ancestors came from Africa, Mediterranean countries, the Arabian Peninsula, India and Spanish-speaking parts of the Americas.[9] In the US it affects about 100,000 people and occurs in about 1 in 500 African Americans and 1 in 1,000 to 1,400 Hispanic Americans.[3] Carrying the hemoglobin S gene protects against serious malaria, which helps explain where it is common.[10]

    How it is inherited

    The disease is caused by variants in the HBB gene, which makes part of hemoglobin, and is inherited in an autosomal recessive pattern.[11]

    Everyone has two copies of the hemoglobin gene, one from each parent. If both parents carry one sickle cell gene, each child has a 1 in 4 chance of sickle cell disease and a 1 in 2 chance of sickle cell trait. People with trait usually have no symptoms but can pass the gene to their children.[12]

    In a couple who are both HbAS carriers, each pregnancy carries a 25% chance of HbSS disease and a 50% chance of HbAS trait, independent of earlier children.[12] Sickle cell anaemia (HbSS) is the most common form; in other forms one beta-globin subunit is hemoglobin S and the other is a different version, such as hemoglobin C.[11]

    In the UK the condition is usually found through pregnancy and newborn screening, including the heel-prick blood spot test.[13]

    Symptoms and emergencies

    Symptoms can start from about 6 months of age and include pain in the bones, joints, muscles or chest, tiredness, swelling of the hands and feet, breathing problems and frequent infections.[14] A sickle cell crisis is a bout of sudden, severe pain that can last hours, days or weeks; dehydration, sudden temperature changes and stress can trigger one.[15]

    Emergency warning signs include a high temperature, chest pain with cough, fever and shortness of breath, which may mean acute chest syndrome, and sudden weakness on one side of the body, confusion or trouble speaking, which may mean a stroke.[16]

    Standard treatment

    • Hydroxyurea, approved in 1998, is an oral medicine that can reduce sickling and help prevent pain crises. L-glutamine and crizanlizumab were approved later.[4]
    • Preventing infection. Daily penicillin lowers young children’s risk of serious infection, alongside vaccinations. Pain relief and blood transfusions are also used.[5]
    • A withdrawn drug. In September 2024 Pfizer withdrew voxelotor (Oxbryta) from the market, saying its benefits did not outweigh its risks.[17]
    • Bone marrow transplant. A blood and bone marrow transplant can cure some people but needs a well-matched donor, usually a close relative. It succeeds in about 90% of children with a matched related donor and is riskier in adults.[6]

    Gene therapies

    On 8 December 2023 the FDA approved Casgevy and Lyfgenia, the first cell-based gene therapies for sickle cell disease, for patients aged 12 and older. Casgevy is the first FDA-approved therapy to use CRISPR/Cas9 genome editing.[7]

    Both start with the patient’s own blood stem cells, which are modified and returned in a one-time infusion after high-dose chemotherapy clears the bone marrow. Casgevy raises production of fetal hemoglobin, which prevents sickling; Lyfgenia uses a lentiviral vector so the cells make a gene-therapy-derived hemoglobin that works like normal adult hemoglobin.[18] For how editing works, see how CRISPR works.

    In the trials FDA reviewed, 29 of 31 evaluable Casgevy patients (93.5%) went at least 12 months in a row without a severe pain crisis, and 28 of 32 Lyfgenia patients (88%) had complete resolution of vaso-occlusive events between 6 and 18 months after infusion.[19] Both approvals rested on single-arm trials, without a comparison group.[20] Blood cancer has occurred in patients treated with Lyfgenia, which carries a boxed warning; patients should have lifelong monitoring.[21]

    Paying for gene therapy

    CMS says the high cost of cell and gene therapies makes it hard for state Medicaid programs to pay for them.[22] Its Cell and Gene Therapy Access Model, first focused on sickle cell disease, is the first time the federal government has negotiated outcomes-based agreements with manufacturers on behalf of state Medicaid agencies. States began joining between January 2025 and January 2026.[8] When checked in November 2026, CMS listed 32 states plus the District of Columbia and Puerto Rico as participants.[23] The wider debate over price and access is covered in the gene therapy access debate.

    Casgevy (exa-cel)

    Casgevy is the first approved CRISPR medicine, an edited stem cell therapy for sickle cell disease and beta-thalassemia. Approvals, data and status.

    More in Health & medicine

    Go deeper

    Questions readers ask

    How is sickle cell disease inherited?

    It is autosomal recessive. If both parents carry one sickle cell gene, each child has a 1 in 4 chance of having the disease and a 1 in 2 chance of having sickle cell trait. People with trait usually have no symptoms but can pass the gene on.[11][12]

    What is a sickle cell crisis?

    A period of sudden, severe pain that can last hours, days or weeks. Dehydration, sudden temperature changes and stress can trigger one.[15]

    When does someone with sickle cell disease need emergency care?

    Warning signs include a high temperature, chest pain with cough and shortness of breath, which may mean acute chest syndrome, and sudden one-sided weakness, confusion or trouble speaking, which may mean a stroke.[16]

    Can sickle cell disease be cured?

    A blood and bone marrow transplant can cure some people but needs a well-matched donor, usually a close relative. Two gene therapies approved in 2023 modify a patient's own stem cells instead.[6][7][18]

    How well do the gene therapies work?

    In the single-arm trials FDA reviewed, 29 of 31 evaluable Casgevy patients had no severe pain crises for at least a year, and 28 of 32 Lyfgenia patients had complete resolution of vaso-occlusive events from 6 to 18 months. Lyfgenia carries a boxed warning for blood cancer.[19][20][21]

    Why is sickle cell common in some regions?

    Carrying one hemoglobin S gene protects against serious malaria, which helps explain why the gene is more common in people whose ancestry traces to areas where malaria is common, such as parts of Africa.[10][9]

    Sources

    · 23 claims from 5 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Sickle cell disease is a group of inherited disorders in which an atypical hemoglobin, hemoglobin S, can distort red blood cells into a sickle or crescent shape. confirmedas of 2026-11-07

    2. [2]

      Sickled red blood cells restrict blood flow and limit oxygen delivery, leading to severe pain and organ damage. confirmedas of 2026-11-07

    3. [3]

      Sickle cell disease affects about 100,000 people in the US and occurs in about 1 in 500 African Americans and 1 in 1,000 to 1,400 Hispanic Americans. confirmedas of 2026-11-07

    4. [4]

      Hydroxyurea, approved in 1998, is an oral medicine that can reduce red-cell sickling and help prevent pain crises; L-glutamine and crizanlizumab were approved later. confirmedas of 2026-11-07

    5. [5]

      Other care includes daily penicillin for young children to prevent serious infections, vaccinations, pain relief and blood transfusions. confirmedas of 2026-11-07

    6. [6]

      A blood and bone marrow transplant can cure some people but needs a well-matched donor, usually a close relative; it succeeds in about 90% of children whose donor is a relative with a matching tissue (HLA) type, and is riskier in adults. confirmedas of 2026-11-07

      • Sickle Cell Disease: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Blood and bone marrow transplant (retrieved 2026-11-07)
      • Sickle Cell Disease: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Blood and bone marrow transplant (retrieved 2026-11-07)
      • Sickle Cell Disease: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Blood and bone marrow transplant (retrieved 2026-11-07)
    7. [7]

      On 8 December 2023 the FDA approved Casgevy and Lyfgenia, the first cell-based gene therapies for sickle cell disease, for patients 12 and older; Casgevy is the first FDA-approved therapy to use CRISPR/Cas9. confirmedas of 2023-12-08

    8. [8]

      CMS's Cell and Gene Therapy Access Model, a voluntary program first focused on sickle cell gene therapy, has CMS negotiate outcomes-based agreements with manufacturers on behalf of state Medicaid programs; states began joining between January 2025 and January 2026. confirmedas of 2026-11-07

    9. [9]

      The disease affects millions worldwide and is most common in people with ancestry from Africa, Mediterranean countries, the Arabian Peninsula, India and Spanish-speaking parts of the Americas. confirmedas of 2026-11-07

    10. [10]

      Studies show that carrying the hemoglobin S gene protects against serious malaria; NHLBI says this explains why the gene is found more often in people whose ancestry traces to areas where malaria is common. confirmedas of 2026-11-07

    11. [11]

      Sickle cell disease is caused by variants in the HBB gene, which makes beta-globin, and is inherited in an autosomal recessive pattern; sickle cell anaemia (HbSS), in which hemoglobin S replaces both beta-globin subunits, is the most common form, while in other forms one subunit is hemoglobin S and the other a different version such as hemoglobin C. confirmedas of 2026-11-07

    12. [12]

      When both parents carry one sickle cell gene, each child, regardless of earlier children, has a 1 in 4 chance of sickle cell disease and a 1 in 2 chance of sickle cell trait; people with trait usually have no symptoms but can pass the gene on. confirmedas of 2026-11-07

    13. [13]

      In the UK sickle cell disease is usually found through pregnancy and newborn screening, including the newborn heel-prick blood spot test. confirmedas of 2026-11-07

      • Sickle cell disease · NHS · Primary source · How sickle cell disease is diagnosed (retrieved 2026-11-07)
      • Sickle cell disease · NHS · Primary source · Screening for sickle cell disease in babies (retrieved 2026-11-07)
    14. [14]

      Symptoms can start from about 6 months of age and include pain in bones, joints, muscles or chest, tiredness, swelling of the hands and feet, breathing problems and frequent infections. confirmedas of 2026-11-07

    15. [15]

      A sickle cell crisis is a period of sudden, severe pain that can last hours, days or weeks, and can be triggered by dehydration, sudden temperature changes and stress. confirmedas of 2026-11-07

    16. [16]

      Emergency warning signs include fever in a person with sickle cell disease, chest pain with cough and shortness of breath (possible acute chest syndrome), and sudden one-sided weakness or trouble speaking (possible stroke). confirmedas of 2026-11-07

    17. [17]

      In September 2024 Pfizer withdrew voxelotor (Oxbryta) from the market, saying its benefits did not outweigh its risks in the approved sickle cell population. confirmedas of 2024-09-30

    18. [18]

      Both therapies modify the patient's own blood stem cells, which are returned as a one-time infusion after high-dose chemotherapy clears the bone marrow; Casgevy raises fetal hemoglobin, while Lyfgenia uses a lentiviral vector so cells make a gene-therapy-derived hemoglobin that works like normal adult hemoglobin. confirmedas of 2023-12-08

    19. [19]

      In the trials FDA reviewed, 29 of 31 evaluable Casgevy patients (93.5%) had no severe pain crises for at least 12 months in a row, and 28 of 32 Lyfgenia patients (88%) had complete resolution of vaso-occlusive events between 6 and 18 months after infusion. confirmedas of 2023-12-08

    20. [20]

      Both approvals rested on single-arm trials without a control group. confirmedas of 2023-12-08

    21. [21]

      Blood cancer has occurred in patients treated with Lyfgenia, and its label carries a boxed warning and calls for lifelong monitoring. confirmedas of 2023-12-08

    22. [22]

      CMS says the high cost of cell and gene therapies makes it difficult for state Medicaid agencies to pay for them. confirmedas of 2026-11-07

    23. [23]

      As listed by CMS when checked in November 2026, 32 states plus the District of Columbia and Puerto Rico participate in the model, with Vertex among the participating manufacturers. confirmedas of 2026-11-07

    Revision history (1)
    1. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Feb 7, 2027.

    Cite this page

    "Sickle cell disease explained: symptoms, inheritance and gene therapy." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/sickle-cell-disease-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.